|
U.S. Congestive Heart Failure Medication Markets
Frost & Sullivan - 6/1/2001 - ID: MC521948
URL: http://www.marketresearch.com/product/display.asp?productid=521948
Electronic Access - Single User - $4,450.00
Electronic Delivery - Global Site License - $5,950.00
Hard Copy Mail Delivery - $4,950.00
Abstract
Emerging Therapeutics Are Poised to Expand the Marketplace
Although angiotensin converting enzyme (ACE) inhibitors and beta blockers continue to dominate the congestive heart failure (CHF) medication markets, a wide array of emerging treatments could significantly expand the therapeutic arsenal against CHF. More than 19 new products are in the research and development pipeline and participants are expected to submit additional
applications to the FDA in the near future.
New therapeutic classes, including angiotensin II receptor blockers and tumor necrosis factor inhibitors, will join a range of products, from natiuretic
peptides to gene therapies, in the quest to effectively prevent, treat, and manage CHF.
This Frost & Sullivan study analyzes the markets for ACE inhibitors, beta blockers, and emerging therapeutics. With its in-depth evaluations of market drivers, restraints, and expert forecasts, this report is an
essential guide to the future of a fast-growing field.
End User Preference Intensifies Competition
"Generic invasion of the CHF market is a substantial threat to the market's overall earnings potential," writes the study's author. Because generic products offer lower prices, manufacturers of branded drugs will be drawn into pricing wars to compete, and many could see revenues decline." The reduction of potential earnings could continue if cost-conscious managed
care organizations and physicians rapidly adopt generics at the expense of branded versions. This report identifies challenges that all industry participants will face, helping your company anticipate and overcome any hurdles that may lay ahead.
Patient and Healthcare Provider Educational Programs Crucial for Industry Winners
"Improving education and bolstering knowledge of patients, physicians, and other healthcare professionals in the CHF medication industry is necessary for optimal treatment and market penetration," says the author. Currently, the level of education in the CHF arena is inadequate for proper therapy administration, maintenance, and product use.
By highlighting previously unexplored areas and offering strategic recommendations about new products and therapies, this research helps to optimize market
penetration, increase product awareness, and maximize gains.
Table of Contents
1. Executive Summary
- A. Market Overview
- 1. Introduction
- 2. Competitive Analysis
- 3. Technologies
- B. Major Research Findings
- 1. Opportunities and Forecasts
- 2. Market Segment Analysis
2. Total Market
- A. Overview and Definitions
- 1. Introduction
- 2. Challenges
- 3. Market Engineering Analysis
- 4. Market Drivers
- 5. Market Restraints
- B. Forecasts and Trends
- 1. Revenue Forecasts
- 2. Demand Analysis
- 3. Market and Technology Trends
- C. Competitive Analysis
- 1. Competitive Structure
- 2. Market Share Analysis
- 3. Product Analysis
- D. Recommendations and Awards
- 1. Strategic Recommendations
- 2. Market Engineering Leadership Award
- 3. Market Engineering Leadership Award, Ace Inhibitor
- 4. Entrepreneurial Company Award: Scios Incorporated
- 5. Product Innovation: Bristol-Myers Squibb Corporation
- 6. Marketing Strategy Awards: King Pharmaceuticals
3. ACE Inhibitor Market
- A. Overview and Definitions
- 1. Introduction
- 2. Challenges
- 3. Market Engineering Analysis
- 4. Market Drivers
- 5. Market Restraints
- B. Forecasts and Trends
- 1. Revenue Forecasts
- 2. Demand Analysis
- 3. Market and Technology Trends
- 4. Pricing Trends
- C. Competitive Analysis
- 1. Competitive Structure
- 2. Market Share Analysis
- 3. Product Analysis
- 4. Off Label Medications
- D. Strategic Recommendations
- 1. Establish Relationships Strategy
- 2. Awareness and Education Strategy
- 3. Reform of Healthcare Payment System Strategy
- 4. Cost Saving Strategy
4. Beta Blockers Market
- A. Overview and Definitions
- 1. Introduction
- 2. Challenges
- 3. Market Engineering Analysis
- 4. Market Drivers
- 5. Market Restraints
- B. Forecasts and Trends
- 1. Revenue Forecasts
- 2. Demand Analysis
- 3. Market and Technology Trends
- 4. Pricing Trends
- C. Competitive Analysis
- 1. Competitive Structure
- 2. Market Share Analysis
- 3. Product Analysis
- 4. Off Label Medications
- D. Recommendations and Evaluation
- 1. Strategic Recommendations
5. Emerging Therapeutics
- A. Overview and Definitions
- 1. Introduction
- 2 Challenges
- 3. Opportunities
- B. Trends
- 1. Market Entrance Forecast
- 2. Demand Analysis
- 3. Market and Technology Trends
- C. Competitive Analysis
- 1. Competitive Structure
- 2. Product Analysis
6. Research Methodology
- A. Terms and Definitions
- 1. Glossary of Terms
- a. Market Definitions
- b. Market Overview
List of Figures
- Chapter 1
- Total Congestive Heart Failure Medications Market: Competitive Structure (U.S.), 2000
- Total Congestive Heart Failure Medications Market: Revenue Forecasts (U.S.), 1997-2007
- Total Congestive Heart Failure Market:Percent of Revenues by Product Type (U.S.),1997-2007
- Chapter 2
- Total Congestive Heart Failure Medications Market: Impact of Top Industry Challenges (U.S.) 2001-2007
- Total Congestive Heart Failure Medications Market: Market Drivers Ranked in Order of Impact (U.S.), 2001-2007
- Total Congestive Heart Failure Medications Market: Market Restraints Ranked in Order of Impact (U.S.), 2001-2007
- Total Congestive Heart Failure Medications Market: Revenue Forecasts (U.S.), 1997-2007
- Total Congestive Heart Failure Market: Percent of Revenues by Product Type (U.S.), 1997-2007
List of Charts
- Chapter 2
- Total Congestive Heart Failure Medications Market: Market Engineering Measurements (U.S.), 2000
- Chapter 3
- Ace Inhibitor Medications Market: Market Engineering Measurements (U.S.), 2000
- Chapter 4
- Beta Blocker Branded Therapeutics Market: Market Engineering Measurements (U.S.), 2000
|